Supporting the Global Launch of a First-in-Class Metabolic Therapy Through Competitive Intelligence

A leading biopharmaceutical company was preparing to launch a first-in-class therapy in the metabolic disease space. The asset had demonstrated strong efficacy signals in multiple Phase III trials and was expected to reshape a high-burden, high-volume category that had seen limited innovation in years.

 

As the asset approached regulatory submission in the US and Europe, the company’s leadership team needed an evidence-backed strategy to differentiate it in a crowded but evolving treatment landscape. They also needed to navigate access and adoption challenges across key markets.

Although the product had strong clinical data, the market was already filled with established treatments from multiple large players. The client faced several important challenges:

• Lack of clarity on how payers and HTA bodies would assess real-world value versus cost in this category
  
• Difficulty identifying clear positioning opportunities without appearing to directly challenge well-entrenched therapies
  
• Internal uncertainty on which markets to prioritize for first-wave rollout based on payer behavior, competitor actions, and regulatory timelines
  
• The need to align global commercial and access teams around a clear, evidence-based strategy
  
  

The complexity of the launch environment made it essential to build a unified global strategy rooted in competitive and market intelligence.

ConsaInsights was engaged to support the global launch planning with a focus on competitor strategy analysis, access environment mapping, and sequencing insights. We worked closely with the global commercial, market access, and medical affairs teams to build a strategy that would reduce uncertainty and speed execution.